152333-94-3

Upstream product

• 121-51-7 3-nitrobenzenesulphonyl chloride 
• 57044-25-4 (R)-oxiranemethanol 
• 556-52-5 oxiranyl-methanol 

Downstream Products

• 5255-75-4 C₉H₉NO₄ 
• 335165-60-1 3[4-(3',4'-dichlorophenyl)piperazinyl]-1,2-epoxypropane 
• 2212-04-6 1-(2-chlorophenoxy)-2,3-epoxypropane 
• 140406-65-1 2-(oxiran-2-ylmethyl)-1,2,3,4-tetrahydroisoquinoline 
• 115314-14-2 (2s)-(+)-glycidyl 3-nitrobenzenesulfonate 
• 115314-14-2 (R)-glycidyl nosylate 
• 5332-66-1 Glycidyl m-nitrophenyl ether 
• 198226-62-9 (+/-)-2-chloro-6-(oxiran-2-ylmethoxy)benzonitrile 
• 1427034-75-0 2-(5-bromo-2-(oxiran-2-ylmethoxy)phenyl)-1H-indole 
• 51997-51-4 4-(2,3-epoxypropoxy)carbazole 
• 133024-37-0 (+/-)-1-benzyloxy-4-(oxiranylmethoxy)naphthalene 
• 98-47-5 3-Nitrobenzenesulfonic acid 
• 111452-72-3 1-(diphenylmethyl)-4-(2,3-epoxypropyl)piperazine 
• 335165-57-6 benzyl-4-(2,3-epoxypropyl)-piperazine 

Relevant academic research and scientific papers

COMPOUNDS USEFUL IN THE TREATMENT OR PREVENTION OF A PRMT5-MEDIATED DISORDER

The present disclosure relates to compounds suitable for the inhibition of protein arginine methyl-transferase (PRMT), in particular PRMT5. These compounds may be for use as therapeutic agents, in particular, agents for use in the treatment and/or prevent

TRICYCLIC COMPOUNDS FOR USE IN TREATMENT OF PROLIFERATIVE DISORDERS

The present invention relates to compounds of Formula (I) as defined herein, and salts, hydrates and solvates thereof. The present invention also relates to pharmaceutical compositions comprising compounds of Formula (I), and to the use of compounds of Formula (I) in the treatment or prevention of PRMT5-mediated disorders, such as cancer.

Synthesis of the calcilytic ligand NPS 2143

(R)-3 (NPS 2143) is a negative allosteric modulator of the human calcium-sensing receptor (CaSR) and as such represents an important pharmacological tool compound for studying the CaSR. Herein, we disclose for the first time a complete experimental description, detailed characterisation and assessment of enantiomeric purity for (R)-3. An efficient, reproducible and scalable synthesis of (R)-3 that requires a minimum of chromatographic purification steps is presented. (R)-3 was obtained in excellent optical purity (er > 99:1) as demonstrated by chiral HPLC and the pharmacological profile for (R)-3 is in full accordance with that reported in the literature.

METHODS OF MAKING COMPOUNDS HAVING A BETA-ADRENERGIC INHIBITOR AND A LINKER AND METHODS OF MAKING COMPOUNDS HAVING A BETA-ADRENERGIC INHIBITOR, A LINKER AND A PHOSPHODIESTERASE INHIBITOR

A method is provided for making compounds comprising a beta -adrenergic inhibiting moiety and a linking moiety, the method comprising: a) reacting a compound of formula (A): (R1 -(CH -O- CH2)) with at least one of NH3, NH

Bispidine antiarrhythmic compounds

There is provided a compound of formula I, wherein R1, R2, R9, R10, R11, R12, X, A and B have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.

Synthesis of enantiomeric 4-hydroxypropranolols from 1,4-dihydroxynaphthalene

Both (R)- and (S)-enantiomers of 4-hydroxypropranolol were effectively prepared from 1,4-dihydroxynaphthalene in eight steps. The overall yields were around 30%.